Results 11 to 20 of about 952,266 (403)
HemaSphere, 2019 Acute myeloid leukemia (AML) occurs with a frequency of 3.5/1,000,000/year cases. AML patients have an invasion of diseased cells (blasts) medullary insufficiency, microenvironmental dysfunction, defects in the proliferation and function of the remaining
H. Döhner +2 more
semanticscholar +4 more sources
Chronic Myeloid Leukemia [PDF]
Hematology, 2003 AbstractChronic myeloid leukemia (CML) was the first human malignancy to be associated with a specific genetic lesion, the Philadelphia chromosome, harboring the BCR-ABL oncogene. Since then, it has become a paradigm for the discovery of molecular mechanisms and targeted therapeutic approaches in the field of hematologic neoplasias. The past 5 years or
Junia V. Melo +2 more
openaire +2 more sources
Acute myeloid leukemia: current progress and future directions
Blood Cancer Journal, 2021 Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML.
H. Kantarjian +8 more
semanticscholar +1 more source
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
New England Journal of Medicine, 2020 BACKGROUND Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.
C. Dinardo +29 more
semanticscholar +1 more source
Advances in acute myeloid leukemia
British medical journal, 2021 Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis ...
L. Newell, R. Cook
semanticscholar +1 more source
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Leukemia, 2020 The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy.
A. Hochhaus +33 more
semanticscholar +1 more source
Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment [PDF]
, 2009 Background: t(9;22) is a balanced translocation, and the chromosome 22 breakpoints (Philadelphia chromosome – Ph+) determine formation of different fusion genes that are associated with either Ph+ acute lymphatic leukemia (Ph+ ALL) or chronic myeloid ...
Henschler, Reinhard +4 more
core +6 more sources
Acute myeloid leukemia: update in diagnosis and treatment in Brazil [PDF]
Einstein (São Paulo), 2011 Objective: To identify how the Brazilian hematology centers treated and diagnosed cases of acute myeloid leukemia in 2009. Methods: An epidemiological observational multicenter study of 11 listed Brazilian centers that treat acute myeloid leukemia and ...
Ricardo Helman +12 more
doaj +3 more sources
Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). [PDF]
, 2011 We report an allelic series of eight mutations in GATA2 underlying Emberger syndrome, an autosomal dominant primary lymphedema associated with a predisposition to acute myeloid leukemia.
C Preudhomme +32 more
core +1 more source
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
The Journal of the National Comprehensive Cancer Network, 2021 The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding ...
D. Pollyea +33 more
semanticscholar +1 more source